NasdaqGM - Delayed Quote USD
ARS Pharmaceuticals, Inc. (SPRY)
Tune into earnings calls Now streaming directly on quote pages.
12.10
-1.25
(-9.36%)
At close: May 14 at 4:00:00 PM EDT
12.15
+0.05
+(0.41%)
Pre-Market: 8:53:23 AM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL | Co-Founder, President, CEO & Director | 3.33M | -- | 1966 |
| Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder & Chief Medical Officer | 2.94M | -- | 1969 |
| Mr. Brian T. Dorsey M.S. | Chief Operating Officer | 706.97k | -- | 1969 |
| Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer | -- | -- | -- |
| Ms. Kathleen D. Scott CPA | Chief Financial Officer | -- | -- | -- |
| Mr. Alexander A. Fitzpatrick Esq. | Chief Legal Officer & Secretary | 677.14k | -- | 1967 |
| Mr. Daniel Relovsky | Senior Vice President of Marketing | -- | -- | -- |
| Mr. Justin Chakma | Chief Business Officer | -- | -- | 1990 |
| Mr. Harris Kaplan M.B.A. | Executive Vice President of Commercial Strategy | -- | -- | 1952 |
| Mr. Eric Karas | Chief Commercial Officer | 618.61k | -- | 1973 |
ARS Pharmaceuticals, Inc.
11682 El Camino Real
Suite 120
San Diego, CA 92130
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 155
Description
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Corporate Governance
ARS Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 4, 2025 at 10:59 AM UTC - August 8, 2025 at 12:00 PM UTC
ARS Pharmaceuticals, Inc. Earnings Date
Recent Events
November 18, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
Related Tickers
SRRK Scholar Rock Holding Corporation
30.54
-2.74%
ARQT Arcutis Biotherapeutics, Inc.
13.60
-1.59%
AKRO Akero Therapeutics, Inc.
37.88
-5.32%
SCPH scPharmaceuticals Inc.
2.2400
-3.45%
VRNA Verona Pharma plc
67.24
-0.49%
ASND Ascendis Pharma A/S
157.20
-2.67%
CRNX Crinetics Pharmaceuticals, Inc.
31.29
+1.10%
URGN UroGen Pharma Ltd.
9.87
-2.66%
RCKT Rocket Pharmaceuticals, Inc.
6.06
-8.47%
RGNX REGENXBIO Inc.
8.33
+1.83%